A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.
|Condition or Disease||Intervention/Treatment||Phase|
Patients initially treated with mantle cell lymphoma were screened for OLR regimen according to study admission criteria. The study will accept up to 24 cycles of treatment until disease progression or intolerable toxicity occurs and subjects voluntarily withdraw informed consent. Patients undergoing hematopoietic stem cell transplantation after complete remission may begin stem cell collection after induction therapy for at least 6 months. Twenty-nine patients are expected to be enrolled
Arms and Interventions
|Experimental: Orelatinib in combination of rituximab and lenalidomide(OLR) Arm|
Induction phase of mantle cell L lymphoma: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1
Drug: Orelabrutinib in in combination of rituximab and lenalidomide(OLR)
Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
Primary Outcome Measures
- Complete response rate [6 cycles,24weeks]
The proportion of patients receiving the treatment with complete remission
Histopathologically confirmed mantle cell lymphoma with chromosomal translocation. All subjects must provide adequate archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.
Age 18-70, both male and female.
No previous systemic treatment for lymphoma.
Have at least one measurable lesion. Measurable disease was defined as measurable tumor masses ≥1.5 cm in one or both dimensions and measurable spleen lesions.
Eastern Oncology Collaboration group physical status score was 0-2.
Adequate hematological function
Life expectancy >3 months.
Have the ability to provide written informed consent and understand and comply with study requirements.
Ability to adhere to research visit schedules and other protocol requirements
Histology conformed blastolytic mantle cell lymphoma and polymorphic mantle cell lymphoma.
Patients with current or suspected central nervous system involvement and history of this disease
Received Bruton's tyrosine kinase inhibitor treatment
Receive lenalidomide treatment
Received other anti-tumor treatments
Major surgery within 4 weeks prior to screening.
Have a history of other active malignant diseases within 2 years prior to study entry,
Systemic fungal, bacterial or viral infection with uncontrolled activity
The following serological states are known for human immunodeficiency virus (HIV) infection or suggest the presence of active hepatitis B or C virus infection
Clinically serious cardiovascular disease
A history of severe hemorrhagic disorders, such as hemophilia A, hemophilia B, von willebrand disease, or A history of spontaneous bleeding requiring blood transfusion or other medical intervention.
A history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months.
A history of major cerebrovascular disease/event, including stroke or intracranial hemorrhage, in the 6 months prior to first administration of the study drug.
Anticoagulant therapy with warfarin or an equivalent vitamin K antagonist or anticoagulant therapy is required within 7 days of initial use of the study drug.
Pregnant or lactating women
Hypersensitivity to any study drug
The presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator considers to be likely to affect the safety of the subject or cause risk
Contacts and Locations
|1||Tianjin Medical University Cancer Insititute & Hospital||Tianjin||Tianjin||China||300181|
Sponsors and Collaborators
- Tianjin Medical University Cancer Institute and Hospital
- Principal Investigator: Huilai Zhang, PHD, Director of Hematology Department
Study Documents (Full-Text)None provided.